Terms: = Pancreatic cancer AND KRAS, C-K-RAS, 3845, P01116, NS3, KI-RAS, KRAS2, K-RAS4A, K-RAS2A, K-RAS4B, KRAS1, K-RAS2B, RASK2 AND Treatment
927 results:
1. Drugging the undruggable: Advances in targeting kras signaling in solid tumors.
Tripathi P; Kumari R; Pathak R
Int Rev Cell Mol Biol; 2024; 385():1-39. PubMed ID: 38663957
[TBL] [Abstract] [Full Text] [Related]
2. A pancreatic cancer organoid-in-matrix platform shows distinct sensitivities to T cell killing.
Lahusen A; Cai J; Schirmbeck R; Wellstein A; Kleger A; Seufferlein T; Eiseler T; Lin YN
Sci Rep; 2024 Apr; 14(1):9377. PubMed ID: 38654067
[TBL] [Abstract] [Full Text] [Related]
3. Disruption of the pro-oncogenic c-RAF-PDE8A complex represents a differentiated approach to treating kras-c-RAF dependent PDAC.
Cooke SF; Wright TA; Sin YY; Ling J; Kyurkchieva E; Phanthaphol N; Mcskimming T; Herbert K; Rebus S; Biankin AV; Chang DK; Baillie GS; Blair CM
Sci Rep; 2024 Apr; 14(1):8998. PubMed ID: 38637546
[TBL] [Abstract] [Full Text] [Related]
4. Decoding the Versatile Landscape of Autophagic Protein VMP1 in cancer: A Comprehensive Review across Tissue Types and Regulatory Mechanisms.
Renna FJ; Gonzalez CD; Vaccaro MI
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612567
[TBL] [Abstract] [Full Text] [Related]
5. Genetic Signature of Human pancreatic cancer and Personalized Targeting.
Reshkin SJ; Cardone RA; Koltai T
Cells; 2024 Mar; 13(7):. PubMed ID: 38607041
[TBL] [Abstract] [Full Text] [Related]
6. [The use of targeted therapies in gastrointestinal oncology].
Lange S
Dtsch Med Wochenschr; 2024 Apr; 149(8):440-446. PubMed ID: 38565117
[TBL] [Abstract] [Full Text] [Related]
7. pancreatic cancer biomarkers: A pathway to advance in personalized treatment selection.
Brozos-Vázquez E; Toledano-Fonseca M; Costa-Fraga N; García-Ortiz MV; Díaz-Lagares Á; Rodríguez-Ariza A; Aranda E; López-López R
Cancer Treat Rev; 2024 Apr; 125():102719. PubMed ID: 38490088
[TBL] [Abstract] [Full Text] [Related]
8. First-in-Class Humanized Antibody against Alternatively Spliced Tissue Factor Augments Anti-Metastatic Efficacy of Chemotherapy in a Preclinical Model of pancreatic Ductal Adenocarcinoma.
Lewis CS; Backman C; Ahsan S; Cliff A; Hariharan A; Yeh JJ; Zhang X; Xie C; Sohal DPS; Bogdanov VY
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473827
[TBL] [Abstract] [Full Text] [Related]
9. PRMT1 promotes pancreatic cancer development and resistance to chemotherapy.
Ku B; Eisenbarth D; Baek S; Jeong TK; Kang JG; Hwang D; Noh MG; Choi C; Choi S; Seol T; Kim H; Kim YH; Woo SM; Kong SY; Lim DS
Cell Rep Med; 2024 Mar; 5(3):101461. PubMed ID: 38460517
[TBL] [Abstract] [Full Text] [Related]
10. Twelve-month progression-free survival with sotorasib and panitumumab in kras G12C mutant metastatic colorectal cancer.
Kavgaci G; Dizdar O; Yalcin S
Anticancer Drugs; 2024 Jun; 35(5):459-461. PubMed ID: 38451823
[TBL] [Abstract] [Full Text] [Related]
11. Glycolysis-non-canonical glutamine dual-metabolism regulation nanodrug enhanced the phototherapy effect for pancreatic ductal adenocarcinoma treatment.
Qiao J; Liu S; Huang Y; Zhu X; Xue C; Wang Y; Xiong H; Yao J
J Colloid Interface Sci; 2024 Jul; 665():477-490. PubMed ID: 38429120
[TBL] [Abstract] [Full Text] [Related]
12. Stress granules-membraneless organelles as therapeutic targets in pancreatic cancer.
Schneider C; Schneider G
EMBO Mol Med; 2024 Mar; 16(3):429-431. PubMed ID: 38413839
[TBL] [Abstract] [Full Text] [Related]
13. Concurrent inhibition of pBADS99 synergistically improves MEK inhibitor efficacy in kras
Tan YQ; Sun B; Zhang X; Zhang S; Guo H; Basappa B; Zhu T; Sethi G; Lobie PE; Pandey V
Cell Death Dis; 2024 Feb; 15(2):173. PubMed ID: 38409090
[TBL] [Abstract] [Full Text] [Related]
14. Cannabigerol Induces Autophagic Cell Death by Inhibiting EGFR-RAS Pathways in Human pancreatic Ductal Adenocarcinoma Cell Lines.
Zeppa L; Aguzzi C; Morelli MB; Marinelli O; Giangrossi M; Luongo M; Amantini C; Santoni G; Nabissi M
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396679
[TBL] [Abstract] [Full Text] [Related]
15. Application of plasma circulating kras mutations as a predictive biomarker for targeted treatment of pancreatic cancer.
Lee MR; Woo SM; Kim MK; Han SS; Park SJ; Lee WJ; Lee DE; Choi SI; Choi W; Yoon KA; Chun JW; Kim YH; Kong SY
Cancer Sci; 2024 Apr; 115(4):1283-1295. PubMed ID: 38348576
[TBL] [Abstract] [Full Text] [Related]
16. The Extracellular Niche and Tumor Microenvironment Enhance kras Inhibitor Efficacy in pancreatic cancer.
Kumarasamy V; Wang J; Frangou C; Wan Y; Dynka A; Rosenheck H; Dey P; Abel EV; Knudsen ES; Witkiewicz AK
Cancer Res; 2024 Apr; 84(7):1115-1132. PubMed ID: 38294344
[TBL] [Abstract] [Full Text] [Related]
17. Ferroptosis: New Strategies and Ideas for the treatment of pancreatic Ductal Adenocarcinoma.
Yang C; Dong Q; Bao H; Ge Y; Xu Z; Li J; Jiang X; Xu Y; Zhong X
Front Biosci (Landmark Ed); 2024 Jan; 29(1):45. PubMed ID: 38287825
[TBL] [Abstract] [Full Text] [Related]
18. Farnesyl-transferase inhibitors show synergistic anticancer effects in combination with novel kras-G12C inhibitors.
Baranyi M; Molnár E; Hegedűs L; Gábriel Z; Petényi FG; Bordás F; Léner V; Ranđelović I; Cserepes M; Tóvári J; Hegedűs B; Tímár J
Br J Cancer; 2024 Apr; 130(6):1059-1072. PubMed ID: 38278976
[TBL] [Abstract] [Full Text] [Related]
19. Multiple medicinal chemistry strategies of targeting kras: State-of-the art and future directions.
Shang Y; Fu S; Hao Q; Ying H; Wang J; Shen T
Bioorg Chem; 2024 Mar; 144():107092. PubMed ID: 38271825
[TBL] [Abstract] [Full Text] [Related]
20. A novel method for detection of pancreatic Ductal Adenocarcinoma using explainable machine learning.
Aslam M; Rajbdad F; Azmat S; Li Z; Boudreaux JP; Thiagarajan R; Yao S; Xu J
Comput Methods Programs Biomed; 2024 Mar; 245():108019. PubMed ID: 38237450
[TBL] [Abstract] [Full Text] [Related]
[Next]
